AMBULATORY PATHWAY FOR ONCOLOGY PATIENTS PRESENTING WITH LOW RISK FEBRILE NEUTROPENIA

*Acute Oncology Neutropenia Working Party*


- This document is offered as a template for use by trusts/hospitals wishing to develop a pathway for the ambulatory management of patients with low risk febrile neutropenia.

- Trusts/hospitals should review content and amend/adapt if required to suit local services prior to approval for local use.

- The user organisation must accept governance responsibility for implementation of the pathway.
Disclaimer
The information contained in this guideline is a consensus of the development and consultation groups’ views on current treatment. It should be used in conjunction with any local policies/procedures/guidelines and should be approved for use according to the trust clinical governance process. Care has been taken in the preparation of the information contained in the guideline. Nevertheless, any person seeking to consult the guideline, apply its recommendations or use its content is expected to use independent, personal medical and/or clinical judgment in the context of the individual clinical circumstances, or to seek out the supervision of a qualified clinician. The group makes no representation or guarantee of any kind whatsoever regarding the guidelines content or its use or application and disclaim any responsibility for its use or application in any way.
1.0 Introduction

Outpatient management of patients with low risk febrile neutropenia (LRFN) identified by a validated risk stratification tool e.g. Multinational Association of Supportive Care in Cancer (MASCC) score [https://www.mascc.org/mascc-fn-risk-index-score](https://www.mascc.org/mascc-fn-risk-index-score) and/or Clinical Index of Stable Febrile Neutropenia (CISNE) [https://www.mdcalc.com/clinical-index-stable-febrile-neutropenia-cisne](https://www.mdcalc.com/clinical-index-stable-febrile-neutropenia-cisne) is a safe and effective strategy.

The benefits include admission avoidance, reducing pressure on often overcrowded and overstretched emergency departments, cost savings, reduced risk of nosocomial infections as well as improved patient experience and satisfaction [1,2,3,4,5].

The National Institute for Health and Care Excellence guideline CG151 recommends considering outpatient antibiotic therapy for patients with confirmed neutropenic sepsis and a low risk of developing septic complications, taking into account the patient's social and clinical circumstances and discussing with them the need to return to hospital promptly if a problem develops [6].

This document is a template for use by trusts/hospitals wishing to develop a pathway for the ambulatory management of patients with a low risk febrile neutropenia of undefined source. It is not intended for use in the management of LRFN in patients who are receiving treatment for Haematological Malignancy.

For governance purposes trusts/hospitals should review and approve the content for local use and amend/adapt if required to suit local services.

2.0 Clinical Workup

Fever in a neutropenic patient is an acute medical emergency.

There is no clinically defined temperature threshold to guide antibiotic prescribing in suspected febrile neutropenia and clinical judgement is required at all times. Patients, receiving systemic anti-cancer therapy (SACT) who contact oncology 24-hour advice lines, or present to the acute setting with a temperature of 37.5°C or above or 36.0°C or below, or who are generally unwell, irrespective of fever, should proceed to urgent clinical assessment as recommended in current UKONS 24-hour triage guidance [7].

Assessment should include:

- A thorough history taken, and examination performed
- Patients with low risk febrile neutropenia will not trigger an aggregate NEWS score of 5 and may not trigger a single NEWS parameter of 3. However, recent chemotherapy is a red flag on the UK Sepsis Trust Pathway – clinicians should commence Sepsis 6 whilst awaiting blood results and completing MASCC risk assessment.

- Take blood for full blood count, urea and electrolytes, liver function tests (including serum albumin), C-reactive protein and lactate along with peripheral blood cultures. Blood cultures should also be taken from any central venous access devices present. A chest x-ray should be performed and/or other specimens, such as MSU sent for culture and sensitivity testing if clinically indicated. Urinalysis may also be helpful. Consider viral illness e.g., influenza and take required swabs. Isolate the patient whilst in the department if indicated
- First dose of empirical intravenous antibiotic therapy administered within 1 hour in all patients where sepsis is suspected
- If Neutropenia confirmed (absolute neutrophil count < 1.0 x10⁹/L) complete MASSC assessment (p.8)

3.0 Defining Patients with Low Risk Febrile Neutropenia

Patients with febrile neutropenia are a heterogeneous group with only a minority of treated patients developing significant medical complications. Once initial workup is performed, a MASCC score should be calculated (p.8). Patients with a MASCC score of 21 or more are at low risk for complications and may be suitable for ambulatory outpatient management. A period of observation is advised to assess and confirm clinical stability, although evidence-based guidance is limited, ASCO/IDSA suggest a period of 4 hours .

4.0 Low Risk Pathway Inclusion Criteria

Fig 1. Primary Inclusion Criteria
4.1 Secondary criteria for inclusion in the low risk pathway:

- History of a temperature of 37.5°C or above or 36.0°C or below 
- First dose of empirical intravenous antibiotic therapy administered
- The patient has ready access to an Emergency Department
- The patient is able to tolerate oral therapy, and there are no other contraindications to commencing oral therapy

N.B. Patients with an identified specific focus of infection should be managed according to local microbiological protocols.

5.0 Clinical Management for Ambulatory Low Risk Febrile Neutropenia

- It is important to consider local sensitivity and resistance patterns in determining the most appropriate regimen, so be guided by local microbiological guidelines.
- If not contraindicated by local/regional guidance, commence oral antimicrobial therapy with oral amoxicillin/clavulanic acid (500/125mg TDS) and ciprofloxacin (500mg BD) subject to local microbiology guidance. If penicillin allergic or known fluoroquinolone resistance, seek local microbiology guidance.
- The duration of oral antibiotics should be determined locally with scope for ongoing review according to clinical response and microbiological culture results
- Advise the patient to complete any prophylactic G-CSF prescribed with their chemotherapy regimen but do not start G-CSF
- Provide additional support treatment as indicated
- Inform the acute oncology team and/or the oncology treating team of assessment and entry onto low risk ambulatory pathway to ensure;
  - clinical follow up and assessment according to agreed LRFN local practice
  - the oncology treating team are aware of this complication and can manage further SACT accordingly

6.0 Requirements to Manage Patients in An Ambulatory Setting

- The patient does not have any of the following conditions that may preclude them from entering onto the low risk pathway:
  - Reduced cognitive function
  - Language barriers
  - Mental health problems
  - Learning difficulties
- The patient understands the signs and symptoms that should trigger them to seek medical assessment and knows when they should return to the hospital (see patient information leaflet on page 12). Check the patient's understanding of the instructions given and their understanding of the potential risks of not following the advice/instructions.
- The patient has a telephone and is able to access the 24-hour specialist oncology advice line.
- The patient has access to a carer and support in the community.
- The patient has transport available should they need to return.
- The patient has ready access to an Emergency Department.
- The patient has an appointment for review by telephone or in an ambulatory setting as per agreed hospital protocol. We recommend review within 48 hours.
- Blood test (FBC) request form completed and given to the patient with instruction for use, if appropriate.

7.0 Clinical Follow Up

- Review the patient by telephone or in an ambulatory setting to assess clinical progress, we recommend that this initial review takes place within 48 hours, further review should be planned according to clinical assessment and progress.
- The assessment should include at least the following key actions:
  - Repeat and review the full blood count if appropriate.
  - Review results of cultures that were taken on initial assessment.
  - Consider rationalising antimicrobials.
  - Inform patient's treating Oncology team.
All patients contacting/presenting with a temperature of 37.5°C or above or 36.0°C or below or generally unwell post SACT, should proceed to urgent clinical assessment as per UKONS 24 Hour Triage guidance. They should have:

- A thorough history taken, examination performed, and observations recorded and reviewed
- Take blood for full blood count, urea and electrolytes, liver function tests (including serum albumin), C-reactive protein and lactate along with peripheral blood cultures. Blood cultures should also be taken from any central venous access devices present. A chest x-ray should be performed and/or other specimens such as MSU, sent for culture and sensitivity testing if clinically indicated. Urinalysis may be helpful. Consider viral illness e.g., influenza and take required swabs.
- Isolate the patient whilst in the department if indicated.
- First dose of empirical intravenous antibiotic therapy administered within 1 hour in all patients where sepsis is suspected.

- Once initial workup is complete, a MASCC score should be calculated (P.8)

**MASCC Score of 21 or more - complete ambulatory low risk febrile neutropenia pathway checklist:**

- Patient is over 18yrs old
- Patient has a solid tumour
- History of a temperature of 37.5°C or above or 36.0°C or below
- Patient has received systemic anti-cancer therapy
- Patient has an absolute neutrophil count <1.0 x 10^9/L
- First dose of empirical intravenous antibiotic therapy administered
- The patient has ready access to an Emergency Department

**The patient should be observed for an agreed minimum period of time to ensure clinical stability. We recommend a minimum of 4 hours**

*If patient remains stable*  
*If the patient’s condition worsens*

**MASCC Score below 21**

- Inpatient management of neutropenic sepsis
- Patient’s condition worsens
- Re-assess NEWS2 and Sepsis Red flags

**Comence oral antimicrobial therapy with amoxicillin/clavulanic acid (500/125mg TDS) and ciprofloxacin (500mg BD)** It is important to consider local sensitivity and resistance patterns in determining the most appropriate regimen so be guided by local microbiological guidelines. If penicillin allergic or known fluorquinolone resistance, seek local microbiology guidance. The duration of oral antibiotics should be determined locally with scope for ongoing review according to clinical response and microbiological culture results

- Advise the patient to complete any prophylactic G-CSF previously prescribed but do not start G-CSF
- Provide additional support treatment as indicated

**Update the Acute Oncology team of assessment and entry onto low risk ambulatory pathway to ensure appropriate follow up and management. (N.B. local reporting/communication pathway may include patient’s treating oncology team)**

- Ensure that the patient has an appointment for review by telephone or in an ambulatory setting as per agreed hospital protocol. We recommend review within 48 hours
- Ensure that the patient has access to 24-hour specialist oncology telephone advice line
- Ensure the patient knows the signs and symptoms that should trigger them to seek medical assessment and know when they should return to the hospital

**Review the patient by telephone or in an ambulatory setting to assess clinical progress. We recommend review within 48 hours:**

- Repeat and review the full blood count if appropriate
- Review results of cultures that were taken on initial assessment
- Consider rationalising antimicrobials
- Inform patient’s treating oncology team
- Further review should be planned according to clinical assessment and patient progress.
8.1 – Multinational Association for Supportive Care in Cancer Risk Score. (MASCC [https://www.mascc.org/mascc-fn-risk-index-score])

### Patient identification details/label

<table>
<thead>
<tr>
<th>Hospital and department:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date and time of arrival:</td>
</tr>
<tr>
<td>Date ...............  Time ...............</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MASCC Risk Index Scoring system</th>
<th>Yes</th>
<th>No</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Burden of illness (febrile neutropenia)</td>
<td>No or mild symptoms</td>
<td>5</td>
<td>0</td>
</tr>
<tr>
<td>(Select only one of these 3 options, points are not cumulative)</td>
<td>Moderate symptoms</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Severe symptoms or moribund</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Is the systolic blood pressure &lt; 90mmHg?</td>
<td>0</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>Does the patient have chronic obstructive pulmonary disease?</td>
<td>0</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>Does the patient have a solid tumour</td>
<td>4</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Is the patient dehydrated requiring IV fluids?</td>
<td>0</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Did the patient develop febrile neutropenia while an outpatient?</td>
<td>3</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Is the patient &lt; 60 years old?</td>
<td>2</td>
<td>0</td>
<td></td>
</tr>
</tbody>
</table>

**Total MASCC Score**

Maximum theoretical score is 26
MASCC score of 21 or more are considered at low risk of septic complications

### Assessment record - MASCC completed by:

Name: Designation: 
Signature: Date:
8.2 Ambulatory Low Risk Febrile Neutropenia Pathway Checklist

### 1. Inclusion criteria:
- Patient is over 18 years of age
- Patient has a solid tumour
- A history a temperature of 37.5°C or above or 36.0°C or below
- Has received systemic anti-cancer treatment
- An absolute neutrophil count <1.0 x 10⁹/L
- Please record neutrophil count here = .... X10⁹/L
- First dose of empirical intravenous antibiotic therapy administered
- MASCC score of 21 or more

If YES to all the above proceed to the action checklist:

### 2. Action checklist:
- History, examination and observations complete
- The following blood tests performed and reviewed:
  - Full Blood Count
  - Urea and electrolytes
  - Liver function tests (including serum albumin)
  - C-reactive protein
  - Lactate
- All blood results above are within acceptable parameters
- Blood samples taken for culture
- MASCC Score calculated =

If blood results are clinically acceptable and the patients MASCC score is 21 or above proceed to ambulatory discharge checklist:

### 3. Ambulatory discharge checklist
- Confirm clinical and patient agreement to proceed to discharge
- The patient has access to a carer and support in the community
Patient verbalises:
1. That they understand the risk of sepsis and that it is a life-threatening condition.
2. They the know signs and symptoms that should alert them to seek medical assessment and are prepared to call and return to the hospital if needed

Patient has ready access to an Emergency Department

Patient written information (see P.12) and emergency contact details including for the 24-hour oncology telephone advice line number provided

The patient has a thermometer and knows how and when to measure their temperature

Confirm that the patient is able to tolerate, and there is no contraindication to oral therapy. Oral antimicrobial therapy prescribed and dispensed

Blood test (FBC) request form completed and given to the patient with instruction for use, if appropriate

Appointment for review by telephone or in an ambulatory setting as per hospital protocol. We recommend review within 48 hours

Local Acute Oncology team/patient's Oncology team updated, and clinical follow up arrangements confirmed

If YES to all of the above: proceed to discharge and ambulatory management.

<table>
<thead>
<tr>
<th>Practitioner record</th>
<th>Checklists 1,2 and 3 completed by:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name:</td>
<td>Designation:          Signature: Date</td>
</tr>
</tbody>
</table>

4. Clinical follow up checklist:

- ✔ yes ✗ no

- Patient reviewed by telephone or in an ambulatory setting to ensure the patient making good clinical progress.
- Repeat the full blood count if appropriate and review the result
- Review results of cultures that were taken on initial assessment.
- If neutrophils have recovered and cultures negative, consider rationalising antimicrobials
- Update patient’s treating Oncology team.
- Further review should be planned according to clinical assessment and patient progress

<table>
<thead>
<tr>
<th>Practitioner record</th>
<th>Clinical Follow up checklist completed by:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name:</td>
<td>Designation: Signature: Date</td>
</tr>
</tbody>
</table>
6. Supplementary notes:

N.B. Please retain a copy of this document for the patients record. Information can be supplemented by freehand text in the notes box above.
You have developed an infection and also currently have a low white blood cell count as a result of your chemotherapy treatment. Your healthcare team have examined you and performed various blood tests, they feel it is safe to discharge you home with antibiotic tablet treatment for your infection. We know this is safe practice and of benefit to patients. However, patients occasionally need to return to hospital and have antibiotics intravenously through a drip.

There is a risk that your infection could develop into sepsis (blood poisoning), which can be a life-threatening complication, so we ask you to be vigilant and contact the **24-hour advice line immediately** if you experience any of the following:

- You feel worse
- You are not improving despite taking the antibiotic tablets as instructed
- You have new or worsening symptoms e.g.
  - Feeling generally unwell, not able to get out of bed. Flu like symptoms - feeling cold and shivery, headaches, aching muscles
  - Change in temperature – 37.5°C or higher OR below 36°C
  - Coughing up green phlegm
  - A sore throat
  - Diarrhoea - 4 or more loose, watery bowel movements in 24 hours
  - Being sick/vomiting
  - Pain or burning when passing urine
  - Skin changes – redness, hotness, swelling or pain
  - Redness, pain, hotness or swelling around your central line if you have one.

**After discharge:**

- You have been given a follow up review appointment. It is very important that this review takes place, so that we are able to monitor your progress and make changes to treatment if required.
- You have been given antibiotic tablets; please take these regularly as directed. Contact the 24-hour advice line if you have any problems in taking the tablets as directed.
- **24 Hour Advice Line Number:** .................................................................
Development Group:

<table>
<thead>
<tr>
<th>Name</th>
<th>Position and Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr Tim Cooksley</td>
<td>Consultant in Acute Medicine&lt;br&gt;The Christie &amp; Manchester University NHS Foundation Trusts&lt;br&gt;Honorary Senior Lecturer, University of Manchester. President Elect of the Society of Acute Medicine.</td>
</tr>
<tr>
<td>Dr Ernie Marshall</td>
<td>Consultant in Medical Oncology and Deputy Medical Director&lt;br&gt;The Clatterbridge Cancer Centre.</td>
</tr>
<tr>
<td>Philippa Jones</td>
<td>Acute Oncology Nurse Advisor, former Acute Oncology lead for UKONS.</td>
</tr>
<tr>
<td>Dr. Alison Young</td>
<td>Consultant in Medical Oncology and Lead for Acute Oncology&lt;br&gt;Leeds Teaching Hospitals</td>
</tr>
<tr>
<td>Dr. Catherine Oakley</td>
<td>Chemotherapy Consultant Nurse, Guys and St Thomas' NHS Foundation Trust.&lt;br&gt;UK Chemotherapy Board Member.</td>
</tr>
<tr>
<td>Dr. Ron Daniels BEM</td>
<td>Consultant in Critical Care at Heart of England NHS Foundation Trust&lt;br&gt;Chief Executive of the UK Sepsis Trust</td>
</tr>
<tr>
<td>Ceri Stubbs</td>
<td>Macmillan Acute Oncology Clinical Nurse Specialist. Velindre NHS Trust, Cardiff</td>
</tr>
<tr>
<td>Dr. Caroline Forde</td>
<td>Clinical Research Fellow, Queens University Belfast</td>
</tr>
<tr>
<td>Lisa Barrott</td>
<td>Chemotherapy Nurse Consultant, The Royal Marsden Hospital.&lt;br&gt;UKONS Board Member.</td>
</tr>
</tbody>
</table>

Consultation:

Professor Donal O’Donoghue, Registrar of the Royal College of Physicians of London, Consultant Renal Physician at Salford Royal and Professor of Renal Medicine at the University of Manchester.

Dr Anne McKillop, MacMillan Consultant in Medical Oncology Acute Oncology, CUP and Lower Gl. The West of Scotland Cancer Centre.

Consultation Groups:

Society of Acute Medicine (SAM)
The UK Chemotherapy Board – representation includes:
Royal College of Physicians (RCP),
Association of Cancer Physicians (ACP),
Royal College of Radiologists (RCR),
Royal College of Pathologists (RCPath).
United Kingdom Oncology Nursing Society (UKONS)
British Oncology Pharmacy Association (BOPA)
References:

1. Klastersky J, Paesmans M. The Multinational Association for Supportive Care in Cancer (MASCC) risk score: 10 years of use for identifying low risk neutropenic cancer patients. Support Care Cancer 2013; 21: 1487-95


7. UKONS. Oncology/Haematology 24 Hour triage tool (2016) https://www.ukons.org


12. IDSA Clinical Practice Guidelines: Clinical Infectious Diseases, Volume 52, Issue 4, 15 February 2011, Pages e56–e93

Ambulatory Pathway for Oncology Patients Presenting with Low Risk Febrile Neutropenia Version 1. November 20th, 2020